Document:

Exhibit 10.4

 

This STOCK PURCHASE AGREEMENT
(the “Agreement”) is made as of February 19, 2018, by and between Blockchain Industries, Inc., a Nevada
corporation with its principal place of business at 53 Calle Palmeras, Suite 802, San Juan, PR 00901 (“BII”)
and LegatumX, Inc. (“LegatumX”), a Delaware corporation (each a Party”, and collectively, the “Parties”).

 

THE PARTIES HEREBY AGREE AS FOLLOWS:

 

1.                 
Purchase and Sale of Stock. Subject to the terms and conditions hereof (including Sections 2, 8 and 9 below),
LegatumX shall sell to BII, and BII shall purchase from LegatumX [●] shares of LegatumX’s common stock, par value $0.0001
per share, (the “Initial Shares”) at a price of [●] per share for an aggregate purchase price of
One Million Three Hundred Thousand (USD $1,300,000) Dollars (the “Purchase Price”). The Initial Shares
shall equal, on a Fully- Diluted Basis (as hereinafter defined), Thirty (30%) percent of the outstanding capital stock of LegatumX
immediately following the Closing Date (as hereinafter defined). “Fully-Diluted Basis” means the aggregate
number of shares in LegatumX calculated as if all outstanding stock options, warrants and convertible securities have been exercised
for or converted into common stock and all options reserved for issuance in the option pool have been issued and exercised for
common stock. **[NTD: The Purchase Price, and the corresponding number of Initial Shares, presumably, will correspond to a total
ascribed value of LegatumX equal to USD

$4,333,333.33].

 

2.              
Consideration and Issuance of LegatumX Shares. The Purchase Price shall consist of Cash Consideration and Stock
Consideration, respectively, each as hereinafter defined.

 

a.               
Cash Consideration. The payments (“Cash Consideration”) to be made by BII to Legatum, and
the corresponding number of Initial Shares allocable thereto, shall be as follows:

 

 

	Amount	 	Payment Date	 	# of Initial Shares	 	Percentage of Total Equity (computed on a Fully-Diluted Basis)
	USD $100,000	 	Closing Date	 	[●]	 	20%
	USD $200,000	 	90 Days Following Closing	 	[●]	 	5%

 

b.              
Stock Consideration. LegatumX shall receive One Hundred Thousand (100,000) shares of common stock of BII (the “BII
Stock”) in exchange for such number of Initial Shares equal to Five (5%) percent of the outstanding capital stock
LegatumX on a Fully- Diluted Basis.

 

c.                Earnout
Adjustment. The Parties acknowledge that BII anticipates filing with the Securities Exchange
Commission (“SEC”) a Form 10 for the registration of the common stock of BII pursuant to Section
12(b) of the Exchange Act (the “Registration Statement”). BII shall use its commercially reasonable
efforts to have the Registration Statement declared effective by the SEC on or before December 31, 2018 (the
“Registration Deadline”). During the one-year period beginning on the date that the Registration
Statement is declared effective by the SEC and ending on the one-year anniversary thereof (the “Earnout
Period”), BII and LegatumX shall cooperate with each other, in good faith, in order to determine a
mutually-agreeable manner and timing for LegatumX to sell the BII Stock (the “Earnout Period
Sales”). If LegatumX realizes gross proceeds on the Earnout Period Sales equal to or exceeding Two
Million Three Hundred Thousand (USD $2,300,000) Dollars, BII shall receive additional shares of LegatumX’s common stock
equal to Five (5%) percent of the outstanding capital stock LegatumX on a Fully- Diluted Basis (the “Lower
Threshold Earnout Shares”). Alternatively, if LegatumX realizes gross proceeds on the Earnout Period Sales
equal to or exceeding Ten Million One Hundred Thousand (USD $10,100,000) Dollars, BII shall receive additional shares of
LegatumX’s common stock equal to Ten (10%) percent of the outstanding capital stock LegatumX on a Fully- Diluted Basis
(the “Higher Threshold Earnout Shares”, and together with the Lower Threshold Earnout Shares, the
“Earnout Shares”).

 

 

 

    	 	1	 

     

    

 

d.              
Mandatory Loan. If, as of the Registration Deadline, BII does not have an effective Registration Statement, reasonably
promptly thereafter, BII shall make a cash advance, or series of cash advances, to LegatumX in the amount of One Million (USD $1,000,000)
Dollars (the “Mandatory Loan”). The Mandatory Loan shall be secured by a first lien priority security
interest in all of the BII Stock and shall bear no interest. The Mandatory Loan shall become immediately due and payable upon the
earlier to occur of (i) the date the Registration Statement is declared effective by the SEC (the “Registration Effective
Date”) or (ii) the sale or issuance by LegatumX of New Securities (as defined in Section 8 below) for cash in a single
transaction or series of transaction resulting in gross proceeds equal to or in excess of Five Million (USD $5,000,000) Dollars
(a “Qualified Capital Raise”). In the event that a Qualified Capital Raise shall precede and occur prior
to the Registration Effective Date, LegatumX repay the full amount of the Mandatory Loan from the proceeds of the Qualified Capital
Raise. Upon the Registration Effective Date, LegatumX shall repay the Mandatory Loan if and in such amount as the Mandatory Loan
shall remain outstanding and unpaid, and the provisions of Section 2.c. above automatically shall apply with respect to the sale
of BII Stock by LegatumX or an affiliate.

 

3.              
Closing. The consummation of the transactions contemplated by this Agreement is herein referred to as the “Closing”,
and the date on which the Closing occurs is herein referred to as the “Closing Date.” The Closing shall
take place via the electronic exchange of documents and signatures at such other time and place as the BII and LegatumX may mutually
agree. At the Closing, LegatumX shall deliver to BII a certificate representing the Initial Shares against payment by BII of the
Cash Consideration by check or wire transfer and delivery by BII of a certificate representing the BII Stock to LegatumX.

 

4.               Optional
Loan Agreement. In consideration of LegatumX entering into this Agreement (and not in consideration of any purchase of
the Initial Shares or with respect to the Earnout Shares), LegatumX shall have the option to obtain a loan from BII in the
principal amount of up to Five Hundred Thousand (USD $500,000) Dollars (the “Optional Loan”) during
the second calendar quarter of 2019. The Optional Loan shall be evidenced by a promissory note, subject to a
commercially reasonable rate of interest, as mutually agreed upon by the Parties, and secured by a pledge of the BII Stock.
The Optional Loan term and maturity schedule shall be determined in the discretion of BII, and the Optional Loan shall be
subject to such other terms and conditions as LegatumX and BII set forth in writing (the “Loan
Agreement”). The Parties shall enter into an “Optional Loan Agreement”, and the full
amount of the Optional Loan shall be transferred to LegatumX, within a commercially reasonable amount of time after written
notice requesting the Optional Loan is provided by LegatumX to BII. For the avoidance of doubt, LegatumX shall have no
obligation to accept the Optional Loan.

 

5.              
Representations and Warranties of LegatumX: LegatumX hereby represents and warrants to BII as follows:

 

a.               
Organization, Standing and Authority; Execution and Delivery; Enforceability. LegatumX is a corporation duly organized,
validly existing and in good standing under the laws of the State of Delaware. LegatumX has all requisite power and authority to
enter into this Agreement and the other documents in order to effectuate the transactions contemplated by this Agreement. All acts
and other proceedings required to be taken by LegatumX to authorize the execution, delivery and performance of this Agreement and
the other transaction documents contemplated hereby and thereby have been duly and properly taken. This Agreement has been duly
executed and delivered by LegatumX and, prior to Closing, LegatumX will have duly executed and delivered each other transaction
document. This Agreement constitutes a legal, valid and binding obligation of LegatumX enforceable against such person in accordance
with its terms.

 

b.              
No Conflicts; Consents; No Default. The execution, delivery and performance by LegatumX of this Agreement, and the
consummation of the transactions contemplated hereby and thereby, do not and will not: (i) conflict with or result in a violation
or breach of any provision of the organizational documents of LegatumX; (b) conflict with or result in a violation or breach of
any provision of any material law or governmental order applicable to LegatumX; (c) require the consent, notice or other action
by any person under, conflict with, result in a violation or breach of, constitute a default or an event that, with or without
notice or lapse of time or both, would constitute a default under, result in the acceleration of or create in any party the right
to accelerate, terminate, modify or cancel, any material contract; or (d) result in the creation or imposition of any encumbrance
on any properties or assets of LegatumX. No consent, approval, permit, governmental order, declaration or filing with, or notice
to, any governmental authority is required by or with respect to LegatumX in connection with the execution and delivery of this
Agreement and the consummation of the transactions contemplated hereby.

 

c.               
Capitalization. The authorized capital stock of the LegatumX, immediately prior to the Closing, consists of [●]
shares of Common Stock, [●] shares of which are issued and outstanding.

 

 

    	 	2	 

     

    

 

d.               Bonus
Plan. Under the LegatumX’s 20 Equity Incentive Plan (the “Plan”), (i) no shares have been
issued pursuant to restricted stock purchase agreements and/or the exercise of outstanding options, (ii) no options have been
granted and are currently outstanding and (iii) [●] shares of Common Stock remain available for future issuance to
officers, directors, employees and consultants of the Company. LegatumX has not made any representations regarding equity
incentives to any officer, employee, director or consultant that are inconsistent with the share amounts and terms set forth
in the Company’s board minutes.

 

e.               
Outstanding Stock. Other than the shares reserved for issuance under the Plan and except as may be granted pursuant
to this Agreement, there are no outstanding options, warrants, rights (including conversion or preemptive rights and rights of
first refusal), proxy or stockholder agreements or agreements of any kind for the purchase or acquisition from LegatumX of any
of its securities.

 

f.               
All issued and outstanding shares of the LegatumX’s common stock (i) have been duly authorized and validly issued
and are fully paid and nonassessable and (ii) were issued in compliance with all applicable state and federal laws concerning the
issuance of securities.

 

g.              
All outstanding shares of common stock, and all shares of common stock issuable upon the exercise or conversion of outstanding
options, warrants or other exercisable or convertible securities are subject to a market standoff or “lockup” agreement
of not less than 180 days following the LegatumX’s initial public offering.

 

h.              
Liabilities. LegatumX has no material liabilities and, to the best of its knowledge no material contingent liabilities,
except current liabilities incurred in the ordinary course of business that have not been, either in any individual case or in
the aggregate, materially adverse.

 

i.                
Intellectual Property.

 

(i)   
LegatumX is, and shall remain in perpetuity, the sole owner of any and all work product created by any of its employees,
officers, or consultants, and of all rights it has in all creative and copyrightable material created by it, trademarks, service
marks and other intellectual property as they may exist or may hereafter be modified by LegatumX (collectively referred to as “LegatumX
IP”). BII acknowledges that any use of LegatumX IP inures to the benefit of LegatumX, including any goodwill, and
that BII will not acquire any ownership in LegatumX IP as a result of this, or any future, Agreement. BII agrees, for itself and
its officers, directors, shareholders, employees, agents and representatives, that all LegatumX IP shall remain and be kept in
strictest confidence and shall not be disclosed to or used by any person or entity without the prior written consent of LegatumX.
The obligation to maintain confidentiality provided herein shall survive any termination or expiration of the term of this Agreement
and may be enforced by injunctive relief or other equitable or legal remedies without the necessity of proving inadequacy of legal
remedies and without proving that LegatumX or any of its respective officers, directors, shareholders, employees, agents and representatives
would suffer irreparable harm as a result of a violation of such confidentiality obligation.

 

(ii)  LegatumX
owns or possesses sufficient legal rights to all patents, trademarks, service marks, trade names, copyrights, trade secrets,
licenses, information and other proprietary rights and processes necessary for its business as now conducted and as presently
proposed to be conducted, without any known infringement of the rights of others. There are no outstanding options, licenses
or agreements of any kind relating to the foregoing proprietary rights, nor is LegatumX bound by or a party to any
options, licenses or agreements of any kind with respect to the patents, trademarks, service marks, trade names, copyrights,
trade secrets, licenses, information and other proprietary rights and processes of any other person or entity other than such
licenses or agreements arising from the purchase of “off the shelf” or standard products.

 

(iii)   
LegatumX has not received any communications alleging that LegatumX has violated or, by conducting its business as presently
proposed to be conducted, would violate any of the patents, trademarks, service marks, trade names, copyrights or trade secrets
or other proprietary rights of any other person or entity.

 

(iv) 
LegatumX is not aware that any of its employees are obligated under any contract (including licenses, covenants or commitments
of any nature) or other agreement, or subject to any judgment, decree or order of any court or administrative agency, that would
interfere with their duties to LegatumX or that would conflict with LegatumX’s business as proposed to be conducted. Each
former and current employee, officer and consultant of LegatumX has executed a proprietary information and inventions agreement.
No former or current employee, officer or consultant of LegatumX has excluded works or inventions made prior to his or her employment
with LegatumX from his or her assignment of inventions pursuant to such employee, officer or consultant’s proprietary information
and inventions agreement. LegatumX does not believe it is or will be necessary to utilize any inventions, trade secrets or proprietary
information of any of its employees made prior to their employment by LegatumX, except for inventions, trade secrets or proprietary
information that have been assigned to LegatumX.

 

 

 

    	 	3	 

     

    

 

j.                
Full Disclosure. LegatumX has provided BII with all information requested by BII in connection with its decision
to enter into this Agreement. Neither this Agreement, the exhibits hereto nor any related agreements contain any untrue statement
of a material fact nor, to the LegatumX’s knowledge, omit to state a material fact necessary in order to make the statements
contained herein or therein not misleading.

 

k.              
Qualified Small Business. LegatumX represents and warrants to BII that, to the best of its knowledge, LegatumX is
a “qualified small business” within the meaning of Section 1202(d) of the Internal Revenue Code, as amended (the “Code”),
as of the date hereof and the Initial Shares should qualify as “qualified small business stock” as defined in Section
1202(c) of the Code as of the date hereof.

 

l.                
Shareholder Lists. Schedule [●] contains true and complete copies of the shareholder list of LegatumX including
the following information with respect to each shareholder of LegatumX (“Shareholder”):

 

	 	(i)	the name and the mailing address of such Shareholder as reflected on the corporate records of the Company;

 

		(ii)	the number of shares of stock of LegatumX held by each suchShareholder; and

		(iii)	such Shareholder’s proportionate share of the total equity capital of LegatumX.

6.              
Representations and Warranties of BII: BII hereby represents and warrants to LegatumX as follows:

 

a.               
Requisite Power and Authority. BII has all necessary power and authority to execute and deliver this Agreement. All
action on BII’s part required for the lawful execution and delivery of this Agreement has been taken. Upon its execution
and delivery, this Agreement will be valid and binding obligations of BII, enforceable in accordance with their terms, except as
limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting enforcement
of creditors’ rights.

 

b.              
Investment Representations. BII understands that the Initial Shares and the Earnout Shares have been registered under
the Securities Act. BII also understands that the Initial Shares are being offered and sold pursuant to an exemption from registration
contained in the Securities Act.

 

c.               
All issued and outstanding shares of BII’s common stock (i) have been duly authorized and validly issued and are fully
paid and nonassessable and (ii) were issued in compliance with all applicable state and federal laws concerning the issuance of
securities.

 

d.              
Full Disclosure. BII has provided LegatumX with all information requested by LegatumX in connection with its decision
to enter into this Agreement. Neither this Agreement, the exhibits hereto nor any related agreements contain any untrue statement
of a material fact nor, to the BII’s knowledge, omit to state a material fact necessary in order to make the statements contained
herein or therein not misleading.

 

7.              
Board Composition: Prior to the completion of a “Qualified Financing” (as hereinafter defined),
the board of directors of LegatumX shall be set and remain at Three (3) directors. BII will have the right (the “Designation
Right”) to elect at any meeting of shareholders of LegatumX at which directors are to be elected, designated and
appointed one (1) member of the board of directors. The parties acknowledge and agree that One (1) member of the board of directors
(the “Independent Director”) shall have no material relationship with either LegatumX or BII. The Independent
Director shall be designated by the mutual agreement of BII and LegatumX. BII shall have no Designation Right following the completion
of a Qualified Financing. A “Qualified Financing” means the sale or issuance by LegatumX of New Securities
(as defined in Section 8 below) for cash in a single transaction or series of transactions resulting in gross proceeds equal to
or in excess of $100 million.

 

8.              
Anti-Dilution Protection. If BII shall, at any time or from time to time after the Closing Date, but on or before
the completion of a Qualified Financing, issue or sell, agree to issue or sell, or be deemed to have issued or sold, any New Securities
(as hereinafter defined), where the price per share paid upon purchase or exercise is, or resultant upon conversion into common
stock of Legatum (taking into account any and all warrants or other securities and other consideration issued in connection therewith
when determining the value of such price per share) would be, less than the Purchase Price, then as a condition precedent to any
such issuance or sale (or deemed issuance or sale), LegatumX shall be required to issue to BII additional shares of common stock
(the “Adjustment Shares”) to maintain BII’s ownership attributable to both (i) the Initial Shares
at Thirty (30%) Percent of LegatumX’s total capital stock on a Fully-Diluted Basis and (ii) the Lower Threshold Earnout
Shares, if applicable, at Five (5%) Percent of LegatumX’s total capital stock on a Fully-Diluted Basis, or alternatively
the Higher Threshold Earnout Shares, if applicable, at Ten (10%) Percent of LegatumX’s total capital stock on a Fully-Diluted
Basis. “New Securities” means shares of the common stock of LegatumX, any other securities, options,
warrants or other rights where upon exercise or conversion the purchaser or recipient receives shares of common stock, or other
securities with similar rights to the common stock. Within thirty (30) days of the sale or issuance of any such New Securities,
LegatumX shall deliver to BII certificates evidencing any Adjustment Shares BII is entitled to hereunder.

 

 

 

    	 	4	 

     

    

 

9.              
Most Favored Nation. Prior to the issuance of any New Securities in an offering (“New Offering”),
LegatumX shall provide BII with a notice (the “MFN Notice”) which shall include a copy of the offering
documentation provided by LegatumX to solicit investment in the New Offering. The MFN Notice shall also describe in reasonable
detail the procedures affording BII the right (“Anti-Dilution Right”) to participate in the New Offering
on substantially similar terms with respect to the average price per share of common stock that an investor pays assuming the full
conversion or exercise of warrants or similar rights that are issued in the New Offering. BII may exercise its Anti-Dilution Right
by providing a notice to such effect to LegatumX on or prior to the date that is thirty (30) days after the date that BII received
the MFN Notice. For avoidance of doubt, the Anti-Dilution Right shall terminate on the date that is the earlier of the date that
the BII does not duly and timely exercise its Anti-Dilution Right as described in this Section 9 or upon the completion of a Qualified
Financing.

 

10.           
Conditions to Closing.

 

a.               
Bringdown Certificate of LegatumX. A certificate in the Form attached hereto as Exhibit [●], duly executed
by an authorized officer of LegatumX as of the Closing Date, in each case to the effect that the conditions set forth in Section
5 have been satisfied.

 

b.              
Bringdown Certificate of BII. A certificate in the Form attached hereto as Exhibit [●], duly executed by an
authorized officer of BII as of the Closing Date, in each case to the effect that the conditions set forth in Section 6 have been
satisfied.

 

c.               
Legal Investment. On the Closing Date, the sale and issuance of the Common Stock shall be legally permitted by all
laws and regulations to which LegatumX is subject.

 

d.               Secretary’s
Certificate. BII shall have received from the LegatumX’s Secretary a certificate in the form attached hereto as
Exhibit [●] and having attached thereto (i) the certificate of incorporation of LegatumX as in effect at the time of
the Closing, (ii) Leguatum’s by-laws as in effect at the time of the Closing, (iii) resolutions approved by the board
of directors of LegatumX authorizing the transactions contemplated hereby, (iv) resolutions approved by
LegatumX’s stockholders authorizing the filing of the restated certificate of incorporation and (v) good standing
certificates with respect to LegatumX dated a recent date before the Closing.

 

e.               
Consents, Permits, and Waivers. LegatumX shall have obtained any and all consents, permits and waivers necessary
or appropriate for consummation of the transactions contemplated by the Agreement and related agreements except for such as may
be properly obtained subsequent to the Closing.

 

f.               
Fiduciary Duties. An agreement in the Form attached hereto as Exhibit [●] shall be executed by each of the
Shareholders and BII as of the Closing Date, pursuant to which each of the Shareholders shall agree to adhere to fiduciary duty
standards, including the duties of loyalty and care, with respect to BII and to avoid conflicts of interest and engaging in any
activity that is directly competitive with the business of BII.

 

11.           
Survival. The representations, warranties, covenants and agreements made herein shall survive the closing of the
transactions contemplated hereby. The representations, warranties, covenants and obligations of either Party, and the rights and
remedies that may be exercised by the other Party, shall not be limited or otherwise affected by or as a result of any information
furnished to, or any investigation made by or knowledge of, either Party or any of its representatives.

 

12.           
Notice. Any notice required by the terms of this Agreement shall be given in writing. It shall be deemed effective
upon (i) personal delivery, (ii) deposit with the United States Postal Service, by registered or certified mail, with postage and
fees prepaid or (iii) deposit with Federal Express Corporation, with shipping charges prepaid. All communications to BII shall
be sent to BII at its principal business address set forth above or at such other address as BII may designate by 10 days’
advance written notice to LegatumX. Notice shall be addressed to LegatumX at the address provided in the signature page to this
Agreement.

 

13.           
Entire Agreement. This Agreement constitutes the entire contract between the parties hereto with regard to the subject
matter hereof. It supersedes any other agreements, representations or understandings (whether oral or written and whether express
or implied) that relate to the subject matter hereof.

 

 

 

    	 	5	 

     

    

 

14.           
Choice of Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Nevada,
as such laws are applied to contracts entered into and performed in such State.

 

15.            Specific
Enforcement. The parties hereto acknowledge that money damages would not be an adequate remedy at law if any party fails
to perform in any material respect any of its obligations hereunder, and accordingly agree that each party, in addition to
any other remedy to which it may be entitled at law or in equity, shall be entitled to seek to compel specific performance of
the obligations of the other party under this Agreement, without the posting of any bond, in accordance with the terms
and conditions of this Agreement in any court of the United States or any State thereof having jurisdiction, and if any
action should be brought in equity to enforce any of the provisions of this Agreement, none of the parties hereto shall raise
the defense that there is an adequate remedy at law. Notwithstanding anything herein to the contrary, Legatum and BII
acknowledge and agree that no specific enforcement shall be available hereunder with respect to any claim against BII arising
under or related to Section 4 hereof, the Loan and/or the Loan Agreement.

 

16.           
Counterparts and Signatures. This Agreement may be executed in one or more counterparts each of which shall be deemed
to be an original and all of which when taken together shall be deemed to be one and the same instrument. Facsimile or electronic
signatures shall have the same meaning and legal effect as ribbon original signatures.

 

 

 

 

 

 

 

 

 

 

    	 	6	 

     

    

 

The parties hereto have
executed this STOCK PURCHASE AGREEMENT as of the date set forth in the first paragraph hereof.

 

	LEGATUMX,INC:	BLOCKCHAIN INDUSTRIES, INC.:
	 	 
	 	 
	By: /s/ James Knippel	By: /s/ Patrick Moynihan
	Name: James Knippel

	Name: Patrick Moynihan

	 	 
	Title: CEO	Title: CEO
	 	 
	Address:	 
	 	 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	7Exhibit 10.5 (i)

 

THIS NOTE AND THE SECURITIES ISSUABLE UPON
THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR UNDER THE SECURITIES LAWS OF ANY STATES IN THE UNITED STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY
AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT
TO REGISTRATION OR EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE
SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE
STATE SECURITIES LAWS.

 

 

PROMISSORY NOTE

 

 

Note Series: 2017C                    

 

Date of Note: January 17, 2018                    

 

Principal Amount of Note: $1,500,000                    

 

For value received AUTOLOTTO, INC.,
a Delaware corporation (the “Company”), promises to pay to the undersigned holder or such party’s
assigns (the “Holder”) the following:

 

		(a)	The principal amount set forth above), and:

 

(i)                
Simple interest on the principal amount at the rate of 1% (One Percent) per annum. Interest shall commence on the
date hereof and shall continue on the outstanding principal amount until paid in full or converted. Interest shall be computed
on the basis of a year of 365 days for the actual number of days elapsed.

 

All unpaid principal payments and interest payments shall be
due and payable, upon the first occurrence of any of the following events (“Qualified Financing”):

 

(i)                The first closing by the Company, or any of its wholly-owned subsidiaries, of an Initial Coin Offering (the “ICO”)
that results in net proceeds to the Company, or its wholly-owned subsidiaries, in an amount which is no less than Twenty Million
Dollars ($20,000,000); or

 

(ii)               the Company's issuance and sale of shares of its equity securities (“Equity Securities”)
to investors (the “Investors”), (excluding the conversion and/or issuance of any note, or other convertible
securities issued for capital raising purposes (e.g., Simple Agreements for Future Equity)), in an amount which is no less
than Twenty Million Dollars ($20,000,000) (the “Series B Financing”)

 

In the event that a Qualified Financing does not take place,
the unpaid principal and interest payments shall convert to Equity Securities as indicated in Section 2 below.

 

The date of the first occurrence of any
of the following will constitute the maturity date: 1) Qualified Financing, or 2) Conversion Date (“Maturity Date”).

 

		1.	BASIC TERMS.

 

(a)               
Payments. All payments of principal and interest
shall be in lawful money of the United States of America and shall be made pro rata among all Holders of Note Series 2017C. All
payments shall be applied first to principal, and thereafter to interest.

 

(b)               
Prepayment. The Company may not prepay this
Note prior to the Maturity Date without the consent of the Holder.

 

 

 

    	 	1	 

     

    

 

 

		2.	CONVERSION AND REPAYMENT.

 

(a)               
Conversion. In the event that the Company
does not complete a Qualified Financing, then the outstanding principal amount of this Note and any unpaid accrued interest shall
automatically convert in whole without any further action by the Holder into Equity Securities on the Second (2nd) Anniversary
of the execution of this Note (the “Conversion Date”), at a conversion price equal to the quotient resulting
from dividing Two Hundred Fifty Million Dollars ($250,000,000) by the number of outstanding shares of common stock of the Company
immediately prior to the Conversion Date (assuming conversion of all preferred classes of shares and of all securities convertible
into common stock and exercise of all outstanding options and warrants, but excluding the shares of equity securities of the Company
issuable upon the conversion of the Notes of Note Series 2017C).

 

(b)               
Change of Control. If the Company consummates
a Change of Control (as defined below) while this Note remains outstanding, the Company shall repay the Holder in cash in an amount
equal to the outstanding principal amount of this Note plus any unpaid accrued interest on the original principal. For purposes
of this Note, a “Change of Control” means (i) a consolidation or merger of the Company with or into any
other corporation or other entity or person, or any other corporate reorganization, other than any such consolidation, merger or
reorganization in which the shares of capital stock of the Company immediately prior to such consolidation, merger or reorganization
continue to represent a majority of the voting power of the surviving entity immediately after such consolidation, merger or reorganization;
(ii) any transaction or series of related transactions to which the Company is a party in which in excess of 50% of the Company’s
voting power is transferred; or (iii) the sale or transfer of all or substantially all of the Company’s assets, or the exclusive
license of all or substantially all of the Company’s material intellectual property; provided that a Change of Control shall
not include any transaction or series of transactions principally for bona fide equity financing purposes in which cash is received
by the Company or any successor, indebtedness of the Company is cancelled or converted or a combination thereof. The Company shall
give the Holder notice of a Change of Control not less than ten (10) days prior to the anticipated date of consummation of the
Change of Control. Any repayment pursuant to this paragraph in connection with a Change of Control shall be subject to any required
tax withholdings, and may be made by the Company (or any party to such Change of Control or its agent) following the Change of
Control in connection with payment procedures established in connection with such Change of Control.

 

(c)               
Procedure for Conversion. In connection with
any conversion of this Note into capital stock, the Holder shall surrender this Note to the Company and deliver to the Company
any documentation reasonably required by the Company (including, in the case of a Qualified Financing, all financing documents
executed by the Investors in connection with such Qualified Financing). The Company shall not be required to issue or deliver the
capital stock into which this Note may convert until the Holder has surrendered this Note to the Company and delivered to the Company
any such documentation. Upon the conversion of this Note into capital stock pursuant to the terms hereof, in lieu of any fractional
shares to which the Holder would otherwise be entitled, the Company shall pay the Holder cash equal to such fraction multiplied
by the price at which this Note converts.

 

(d)               
Interest Accrual. If a Change of Control or
Qualified Financing is consummated, all interest on this Note shall be deemed to have stopped accruing as of a date selected by
the Company that is up to ten (10) days prior to the signing of the definitive agreement for the Change of Control or Qualified
Financing.

 

		3.	REPRESENTATIONS AND WARRANTIES.

 

(a)               
Representations and Warranties of the Company.
The Company hereby represents and warrants to the Holder as of the date the first Note was issued as follows:

 

(i)                
Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in
good standing under the laws of the State of Delaware. The Company has the requisite corporate power to own and operate its properties
and assets and to carry on its business as now conducted and as proposed to be conducted. The Company is duly qualified and is
authorized to do business and is in good standing as a foreign corporation in all jurisdictions in which the nature of its activities
and of its properties (both owned and leased) makes such qualification necessary, except for those jurisdictions in which failure
to do so would not have a material adverse effect on the Company or its business (a “Material Adverse Effect”).

 

(ii)              
Corporate Power. The Company has all requisite corporate power to issue this Note and to carry out and perform its obligations
under this Note. The Company’s Board of Directors (the “Board”) has approved the issuance of this
Note based upon a reasonable belief that the issuance of this Note is appropriate for the Company after reasonable inquiry concerning
the Company’s financing objectives and financial situation.

 

 

 

    	 	2	 

     

    

 

(iii)             
Authorization. The requisite corporate resolutions necessary for the issuance and delivery of this Note have been executed.
This Note constitutes a valid and binding obligation of the Company enforceable in accordance with its terms, subject to laws of
general application relating to bankruptcy, insolvency, the relief of debtors and, with respect to rights to indemnity, subject
to federal and state securities laws. Any securities issued upon conversion of this Note (the “Conversion Securities”),
when issued in compliance with the provisions of this Note, will be validly issued, fully paid, nonassessable, free of any liens
or encumbrances and issued in compliance with all applicable federal and securities laws.

 

(iv)             
Personal Guarantee. The undersigned corporate officers, by affixing their signatures below, do hereby agree to assume
personal responsibility to Holder in the event of default (as defined in Section 5 below) or noncompliance by the Company. The
responsibility of the individual guarantors shall accrue for all obligations due to Holder under this Note and the applicable laws.

 

(v)               
Governmental Consents. To the best of its knowledge, the Company has obtained all consents, approvals, orders or authorizations
of, or registrations, qualifications, designations, declarations or filings with, any governmental authority which may be required
on the part of the Company in connection with issuance of this Note.

 

(vi)             
Compliance with Laws. To the best of its knowledge, the Company is not in violation of any applicable statute, rule,
regulation, order or restriction of any domestic or foreign government or any instrumentality or agency thereof in respect of the
conduct of its business or the ownership of its properties, which violation of which would have a Material Adverse Effect.

 

(vii)           
Compliance with Other Instruments. The Company is not in violation or default of any term of its certificate of incorporation
or bylaws, or of any provision of any mortgage, indenture or contract to which it is a party and by which it is bound or of any
judgment, decree, order or writ, other than such violation(s) that would not have a Material Adverse Effect.

 

(viii)         
No “Bad Actor” Disqualification. The Company has exercised reasonable care to determine whether any Company
Covered Person (as defined below) is subject to any of the “bad actor” disqualifications described in Rule 506(d)(1)(i)
through (viii), as modified by Rules 506(d)(2) and (d)(3), under the Act (“Disqualification Events”).
To the Company’s knowledge, no Company Covered Person is subject to a Disqualification Event. The Company has complied, to
the extent required, with any disclosure obligations under Rule 506(e) under the Act. For purposes of this Note, “Company
Covered Persons” are those persons specified in Rule 506(d)(1) under the Act; provided, however, that Company Covered
Persons do not include (a) any Holder, or (b) any person or entity that is deemed to be an affiliated issuer of the Company solely
as a result of the relationship between the Company and any Holder.

 

(ix)             
Offering. Assuming the accuracy of the representations and warranties of the Holder contained in subsection (b) below,
the offer, issue and sale of this Note and the Conversion Securities (collectively, the “Securities”)
are and will be exempt from the registration and prospectus delivery requirements of the Act, and have been registered or qualified
(or are exempt from registration and qualification) under the registration, permit or qualification requirements of all applicable
state securities laws.

 

(x)               
Use of Proceeds. The Company shall use the proceeds of this Note solely for the operations of its business, and not
for any personal, family or household purpose.

 

(b)               
Representations and Warranties of the Holder.
The Holder hereby represents and warrants to the Company as of the date hereof as follows:

 

(i)                
Purchase for Own Account. The Holder is acquiring the Securities solely for the Holder’s own account and beneficial
interest for investment and not for sale or with a view to distribution of the Securities or any part thereof, has no present intention
of selling (in connection with a distribution or otherwise), granting any participation in, or otherwise distributing the same,
and does not presently have reason to anticipate a change in such intention.

 

 

 

    	 	3	 

     

    

 

(ii)              
Information and Sophistication. Without lessening or obviating the representations and warranties of the Company set
forth in subsection (a) above, the Holder hereby: (A) acknowledges that the Holder has received all the information the Holder
has requested from the Company and the Holder considers necessary or appropriate for deciding whether to acquire the Securities,
(B) represents that the Holder has had an opportunity to ask questions and receive answers from the Company regarding the terms
and conditions of the offering of the Securities and to obtain any additional information necessary to verify the accuracy of the
information given the Holder and (C) further represents that the Holder has such knowledge and experience in financial and business
matters that the Holder is capable of evaluating the merits and risk of this investment.

 

(iii)             
Ability to Bear Economic Risk. The Holder acknowledges that investment in the Securities involves a high degree of risk,
and represents that the Holder is able, without materially impairing the Holder’s financial condition, to hold the Securities
for an indefinite period of time and to suffer a complete loss of the Holder’s investment.

 

(iv)             
Further Limitations on Disposition. Without in any way limiting the representations set forth above, the Holder further
agrees not to make any disposition of all or any portion of the Securities unless and until:

 

(1)                                                  
There is then in effect a registration statement under the Act covering such proposed disposition and such disposition
is made in accordance with such registration statement; or

 

(2)                                                  
The Holder shall have notified the Company of the proposed disposition and furnished the Company with a detailed statement
of the circumstances surrounding the proposed disposition, and if reasonably requested by the Company, the Holder shall have furnished
the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration
under the Act or any applicable state securities laws; provided that no such opinion shall be required for dispositions in compliance
with Rule 144 under the Act, except in unusual circumstances.

 

(3)                                                  
Notwithstanding the provisions of paragraphs (1) and (2) above, no such registration statement or opinion of counsel
shall be necessary for a transfer by the Holder to a partner (or retired partner) or member (or retired member) of the Holder in
accordance with partnership or limited liability company interests, or transfers by gift, will or intestate succession to any spouse
or lineal descendants or ancestors, if all transferees agree in writing to be subject to the terms hereof to the same extent as
if they were the Holders hereunder.

 

(v)               
Accredited Investor Status. The Holder is an “accredited investor” as such term is defined in Rule 501 under
the Act.

 

(vi)             
No “Bad Actor” Disqualification. The Holder represents and warrants that neither (A) the Holder nor (B)
any entity that controls the Holder or is under the control of, or under common control with, the Holder, is subject to any Disqualification
Event, except for Disqualification Events covered by Rule 506(d)(2)(ii) or (iii) or (d)(3) under the Act and disclosed in writing
in reasonable detail to the Company. The Holder represents that the Holder has exercised reasonable care to determine the accuracy
of the representation made by the Holder in this paragraph, and agrees to notify the Company if the Holder becomes aware of any
fact that makes the representation given by the Holder hereunder inaccurate.

 

(vii)           
Foreign Investors. If the Holder is not a United States person (as defined by Section 7701(a)(30) of the Internal Revenue
Code of 1986, as amended (the “Code”)), the Holder hereby represents that he, she or it has satisfied
itself as to the full observance of the laws of the Holder’s jurisdiction in connection with any invitation to subscribe
for the Securities or any use of this Note, including (A) the legal requirements within the Holder’s jurisdiction for the
purchase of the Securities, (B) any foreign exchange restrictions applicable to such purchase, (C) any governmental or other consents
that may need to be obtained, and (D) the income tax and other tax consequences, if any, that may be relevant to the purchase,
holding, redemption, sale or transfer of the Securities. The Holder’s subscription, payment for and continued beneficial
ownership of the Securities will not violate any applicable securities or other laws of the Holder’s jurisdiction.

 

(viii)         
Forward-Looking Statements. With respect to any forecasts, projections of results and other forward-looking statements
and information provided to the Holder, the Holder acknowledges that such statements were prepared based upon assumptions deemed
reasonable by the Company at the time of preparation. There is no assurance that such statements will prove accurate, and the Company
has no obligation to update such statements.

 

 

 

    	 	4	 

     

    

 

		4.	EVENTS OF DEFAULT.

 

(a)               
If there shall be any Event of Default (as defined below) hereunder, at the option and
upon the declaration of the Holder and upon written notice to the Company (which election and notice shall not be required in the
case of an Event of Default under subsection (ii) or (iii) below), this Note shall accelerate and all principal and unpaid accrued
interest shall become due and payable. The occurrence of any one or more of the following shall constitute an “Event
of Default”:

 

(i)                
The Company fails to pay timely any of the principal amount due under this Note on the date the same becomes due and
payable or any unpaid accrued interest or other amounts due under this Note on the date the same becomes due and payable;

 

(ii)              
The Company files any petition or action for relief under any bankruptcy, reorganization, insolvency or moratorium law
or any other law for the relief of, or relating to, debtors, now or hereafter in effect, or makes any assignment for the benefit
of creditors or takes any corporate action in furtherance of any of the foregoing; or

 

(iii)             
An involuntary petition is filed against the Company (unless such petition is dismissed or discharged within 60 days
under any bankruptcy statute, now or hereafter in effect, or a custodian, receiver, trustee or assignee for the benefit of creditors
(or other similar official) is appointed to take possession, custody or control of any property of the Company).

 

(b)               
In the event of any Event of Default hereunder, the Company shall pay all reasonable attorneys’
fees and court costs incurred by the Holder in enforcing and collecting this Note.

 

(c)               
Upon the occurrence and during the continuance of an Event of Default (as defined in Subsections
5a-i to 5a-iii above), this Note shall bear interest at a default rate of 1% (One Percent) per annum.

 

		5.	MISCELLANEOUS PROVISIONS.

 

(a)               
Waivers. The Company hereby waives demand,
notice, presentment, protest and notice of dishonor.

 

(b)               
Further Assurances. The Holder agrees and
covenants that at any time and from time to time the Holder will promptly execute and deliver to the Company such further instruments
and documents and take such further action as the Company may reasonably require in order to carry out the full intent and purpose
of this Note and to comply with state or federal securities laws or other regulatory approvals.

 

(c)               
Transfers of Notes. This Note may be transferred
only upon its surrender to the Company for registration of transfer, duly endorsed, or accompanied by a duly executed written instrument
of transfer in form satisfactory to the Company. Thereupon, this Note shall be reissued to, and registered in the name of, the
transferee, or a new Note for like principal amount and interest shall be issued to, and registered in the name of, the transferee.
Principal shall be paid solely to the registered holder of this Note. Such payment shall constitute full discharge of the Company’s
obligation to pay such Principal.

 

(d)               
Market Standoff. To the extent requested by
the Company or an underwriter of securities of the Company, each Holder and any permitted transferee thereof shall not, without
the prior written consent of the managing underwriters in the IPO (as hereafter defined), offer, sell, make any short sale of,
grant or sell any option for the purchase of, lend, pledge, otherwise transfer or dispose of (directly or indirectly), enter into
any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership (whether
any such transaction is described above or is to be settled by delivery of Securities or other securities, in cash, or otherwise),
any Securities or other shares of stock of the Company then owned by such Holder or any transferee thereof, or enter into an agreement
to do any of the foregoing, for up to 180 days following the effective date of the registration statement of the initial public
offering of the Company (the “IPO”) filed under the Securities Act. For purposes of this paragraph, “Company”
includes any wholly owned subsidiary of the Company into which the Company merges or consolidates. The Company may place restrictive
legends on the certificates representing the shares subject to this paragraph and may impose stop transfer instructions with respect
to the Securities and such other shares of stock of each Holder and any transferee thereof (and the shares or securities of every
other person subject to the foregoing restriction) until the end of such period. Each Holder and any transferee thereof shall enter
into any agreement reasonably required by the underwriters to the IPO to implement the foregoing within any reasonable timeframe
so requested. The underwriters for any IPO are intended third party beneficiaries of this paragraph and shall have the right, power
and authority to enforce the provisions of this paragraph as though they were parties hereto.

 

 

 

    	 	5	 

     

    

 

(e)               
Amendment and Waiver. Any term of this Note
may be amended or waived with the written consent of the Company and the Holder. Upon the effectuation of such waiver or amendment
with the consent of the Holder in conformance with this paragraph, such amendment or waiver shall be effective as to, and binding
against the holders of, all of the Notes, and the Company shall promptly give written notice thereof to the Holder if the Holder
has not previously consented to such amendment or waiver in writing; provided that the failure to give such notice shall not affect
the validity of such amendment or waiver.

 

(f)                
Governing Law. This Note shall be governed
by and construed under the laws of the State of Delaware, as applied to agreements among Delaware residents, made and to be performed
entirely within the State of Delaware, without giving effect to conflicts of laws principles.

 

(g)               
Binding Agreement. The terms and conditions
of this Note shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in
this Note, expressed or implied, is intended to confer upon any third party any rights, remedies, obligations or liabilities under
or by reason of this Note, except as expressly provided in this Note.

 

(h)               
Counterparts; Manner of Delivery. This Note
may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature
complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission
method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for
all purposes.

 

(i)                
Titles and Subtitles. The titles and subtitles
used in this Note are used for convenience only and are not to be considered in construing or interpreting this Note.

 

(j)                
Notices. All notices required or permitted
hereunder shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii)
when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, if not, then on the
next business day, (iii) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid,
or (iv) one day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification
of receipt. All communications to a party shall be sent to the party’s address set forth on the signature page hereto or
at such other address(es) as such party may designate by 10 days’ advance written notice to the other party hereto. A copy
of any notice to the Company shall be sent to Cooley LLP, 101 California Street, 5th Floor, San Francisco, CA 94111-5800, Attn:
Amanda C. Busch, e-mail: abusch@cooley.com.

 

(k)               
Expenses. The Company and the Holder shall
each bear its respective expenses and legal fees incurred with respect to the negotiation, execution and delivery of this Note
and the transactions contemplated herein.

 

(l)                
Waiver of Conflicts. Each party to this Note
acknowledges that Cooley LLP (“Cooley”), outside general counsel to the Company, has in the past performed
and is or may now or in the future represent the Holder or the Holder’s affiliates in matters unrelated to the transactions
contemplated by this Note (the “Note Financing”), including representation of the Holder or the Holder’s
affiliates in matters of a similar nature to the Note Financing. The applicable rules of professional conduct require that Cooley
inform the parties hereunder of this representation and obtain their consent. Cooley has served as outside general counsel to the
Company and has negotiated the terms of the Note Financing solely on behalf of the Company. The Company and the Holder hereby (i)
acknowledge that they have had an opportunity to ask for and have obtained information relevant to such representation, including
disclosure of the reasonably foreseeable adverse consequences of such representation; (ii) acknowledge that with respect to the
Note Financing, Cooley has represented solely the Company, and not any Holder or any stockholder, Board member or employee of the
Company or director, stockholder or employee of the Holder; and (iii) gives the Holder’s informed consent to Cooley’s
representation of the Company in the Note Financing.

 

(m)             
Delays or Omissions. It is agreed that no
delay or omission to exercise any right, power or remedy accruing to the Holder, upon any breach or default of the Company under
this Note shall impair any such right, power or remedy, nor shall it be construed to be a waiver of any such breach or default,
or any acquiescence therein, or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach
or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. It is further agreed that any
waiver, permit, consent or approval of any kind or character by the Holder of any breach or default under this Note, or any waiver
by the Holder of any provisions or conditions of this Note, must be in writing and shall be effective only to the extent specifically
set forth in writing and that all remedies, either under this Note, or by law or otherwise afforded to the Holder, shall be cumulative
and not alternative. This Note shall be void and of no force or effect in the event that the Holder fails to remit the full principal
amount to the Company within five (5) calendar days of the date of this Note.

 

 

 

    	 	6	 

     

    

 

(n)               
Entire Agreement. This Note constitutes the
full and entire understanding and agreement between the parties with regard to the subjects hereof, and no party shall be liable
or bound to any other party in any manner by any representations, warranties, covenants and agreements except as specifically set
forth herein.

 

(o)               
Exculpation among Holders. The Holder acknowledges
that the Holder is not relying on any person, firm or corporation, other than the Company and its officers and Board members, in
making its investment or decision to invest in the Company.

 

(p)               
Broker’s Fees. Each party hereto represents
and warrants that no agent, broker, investment banker, person or firm acting on behalf of or under the authority of such party
hereto is or will be entitled to any broker’s or finder’s fee or any other commission directly or indirectly in connection
with the transactions contemplated herein. Each party hereto further agrees to indemnify each other party for any claims, losses
or expenses incurred by such other party as a result of the representation in this subsection being untrue.

 

(q)               
California Corporate Securities Law. THE SALE
OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS NOTE HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE
OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION THEREFOR PRIOR TO
SUCH QUALIFICATION OR IN THE ABSENCE OF AN EXEMPTION FROM SUCH QUALIFICATION IS UNLAWFUL. PRIOR TO ACCEPTANCE OF SUCH CONSIDERATION
BY THE COMPANY, THE RIGHTS OF ALL PARTIES TO THIS NOTE ARE EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED OR AN EXEMPTION
FROM SUCH QUALIFICATION BEING AVAILABLE.

 

 

[Signature pages follow]

 

 

 

    	 	7	 

     

    

 

The parties have executed this PROMISSORY NOTE as of
the date first noted above.

 

 

	 	HOLDER (if an entity):
	 	 
	 	Name of Holder: Blockchain Industries, Inc.
	 	 
	 	By:   /s/ Patrick Moynihan
	 	Name: Patrick Moynihan
	 	Title:Chairman/CEO
	 	 
	 	E-mail:patrick@blockchainind.com
	 	 
	 	Address: ___________________________
	 	                  ___________________________
	 	                  ___________________________
	 	 
	 	HOLDER (if an individual):
	 	 
	 	Name of Holder: ______________________
	 	 
	 	 
	 	Signature: __________________________
	 	 
	 	E-mail: ______________________
	 	 
	 	Address: _________________________

 

 

 

 

SIGNATURE PAGE TO

AUTOLOTTO,
INC.

PROMISSORY NOTE

 

 

    	 	8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}]]